Lead program
Our lead program in hematologic malignancies targets an "Eat Me" signal upregulated on B cell and myeloid tumors.
Our lead program in hematologic malignancies targets an "Eat Me" signal upregulated on B cell and myeloid tumors.
Product Candidates | Indications | Stages |
---|---|---|
Home Malignancies | ||
CER-1236 (Lead Program) |
Hematology | IND-enabling |
Solid Tumors | ||
CER-1236 | Solid Tumor | Pre-Clinical |